Diabetes and chronic kidney disease by Van Rensburg, BWJ
When insulin was discovered decades ago, the possibility arose 
that diabetes mellitus could have been cured but, alas, the long-
term complications were realised only later. Today diabetic 
nephropathy (DN) is a leading cause of end-stage renal disease 
(ESRD) in Western societies.1 It is the single largest cause of ESRD 
in adult Americans and Europeans, accounting for over a third of 
all patients beginning renal replacement therapy.  As South Africa 
becomes more affluent and more inhabitants assume a Western 
style of living, we can expect a similar situation to develop here. The 
additional tragedy in our setting is that many diabetics are refused 
chronic dialysis or transplantation due to significant extrarenal 
disease, mainly cardiovascular, that precludes renal replacement 
therapy in the public sector.2
Clinical pic ture and natural course
Both type 1 and type 2 diabetics may develop DN, males have a 
slightly higher propensity for developing DN and ethnic background 
may play a role, with native Americans, African Americans and 
south Asians more likely to be affected.
The hallmark of established DN is proteinuria, often severe enough 
to be classified as nephrotic syndrome. In the natural history of 
DN, Mogensen identified 5 stages of renal dysfunction (Table I).3 
These are more clearly defined in type 1 diabetics, mainly because 
they often present with metabolic complications early after onset 
of diabetes, while type 2 diabetics may have a very insidious onset 
and they may have been exposed to a much longer period of 
hyperglycaemia before the diagnosis is made.
Hyperfiltration
Hyperfiltration is common in early diabetics and is suspected to be 
due to increased glomerular capillary pressure in the glomerulus, 
mainly mediated by afferent vasodilatation. It may be partly 
responsible for progressive renal damage. Measures that reduce 
glomerular pressure such as reduction of systemic blood pressure, 
low-protein diet (which blocks afferent arteriolar dilatation) or 
ACE inhibition (which blocks angiotensin-mediated efferent 
vasoconstriction) all slow down the development of glomerular 
damage and proteinuria.1 The hyperfiltration is associated with 
hypertrophy (glomeruli) and proliferation (tubulointerstitial 
structures) with several centimeters’ increase in renal size.  These 
changes improve with good glucose control.
Microalbuminuria (after 5 - 15 years)
Small amounts of normal s-albumin may occur in the urine of 
healthy non-diabetic persons, but should not exceed 30 mg in 
24 hours. The amount may vary by 40% on different days, and is 
affected by strenuous exercise, oral protein intake, fluid loading, 
urinary tract infection and pregnancy. On average urinary albumin 
excretion rate (UAER) is 25% higher during the daytime. To make 
the diagnosis of microalbuminuria, 2 of 3 consecutive collections 
in a 3-month period should be in the microalbuminuric range 
(30 – 300 mg/24 h). It is more practical to use the urine albumin 
creatinine ratio (ACR) on early-morning urine, because it obviates 
the need for a timed urine sample. Values above 2.5 mg/mmol are 
indicative of microalbuminuria.
Screening
All type 1 diabetics over 12 years of age should be screened annually 
for microalbuminuria from 5 years after the diagnosis of diabetes 
has been made, while type 2 diabetics should start immediately 
with annual screening. If the morning AER is elevated it should be 
confirmed with timed specimens and followed 6 monthly. Patients 
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 Today diabetic nephropathy 
(DN) is a leading cause of 
end-stage renal disease 
(ESRD) in Western societies.
 The hallmark of established 
DN is proteinuria, often 
severe enough to be 
classified as nephrotic 
syndrome.
Table I. Stages of diabetic nephropathy
•    Stage 1: Renal hypertrophy and hyperfiltration – glomeru-
lar filtration rate may be increased 20 - 40%
•    Stage 2: Is clinically ‘silent’ but hyperfiltration persists and 
is correlated with mild hyperglycaemia
•    Stage 3: Microalbuminuria is present
•    Stage 4: Overt nephropathy with proteinuria, hypertension 
and progressive renal failure
•    Stage 5: End-stage renal failure develops  
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D iab etes
with microalbuminuria should receive a 
drug acting against angiotensin, irrespective 
of blood pressure.
Associated conditions
•    Microangiopathy. The glomerular filter 
consists, among others, of a tuft of capillary 
vessels that forms part of the filter in the 
kidney. In healthy persons, molecules 
from the size of albumin and larger are 
prevented from passing into the urine by 
these structures. Early disease of small 
blood vessels (endothelial dysfunction) 
can thus be detected by the presence of 
albumin in the urine, and correlates with 
clinical evidence of microangiopathy 
(retinopathy and neuropathy). One of 
the few places where small blood vessels 
can be observed directly is in the retina – 
clinicians should therefore not lose their 
ability to use an ophthalmoscope.
•    Hypertension. Blood pressure tends to 
rise once proteinuria becomes evident, 
and the normal nocturnal dipping 
of blood pressure on ambulatory 
monitoring becomes less.  An important 
mechanism of hypertension is sodium 
and water retention with volume- 
mediated hypertension.
•    Cardiovascular disease. The presence 
of microalbuminuria is a predictor of 
cardiovascular morbidity and mortality, 
including coronary heart disease, silent 
myocardial ischaemia and left ventricular 
hypertrophy.
 
•    Hyperlipidaemia. Hypertrygliceridae-
mia, lower HDL and higher LDL 
cholesterol occur as microalbuminuria 
increases. These should be managed in 
their own right.
Overt proteinuria 
When diabetic patients develop proteinuria 
the clinical question usually arises whether 
diabetic nephropathy can be accepted and 
whether the patient should have a renal 
biopsy or other investigation to exclude other 
treatable renal disease. The usual indications1 
for a biopsy or other investigations are 
summarised in Table II.
Important other renal conditions occur in 
diabetics and should be kept in mind:
•    renal papillary necrosis
•    renovascular disease
•    autonomic neuropathy of the bladder
•    urinary tract infections
•    contrast nephrotoxicity.
Renal failure
End-stage renal failure occurs a median of 
7 years after overt proteinuria.
As renal function declines, two things 
happen that may give patients the impression 
that they are improving, while in fact the 
opposite may be true. Less insulin may be 
required daily to control the sugar due to 
less catabolism of insulin in the diseased 
kidney, and the nephrotic syndrome may 
improve clinically (less swelling) because the 
surface area for filtration of the glomeruli is 
diminishing.  Diabetic nephropathy is one of 
the causes of patients presenting with end-
stage renal disease and relatively normal- 
sized kidneys. All forms of renal replacement 
therapies may be used in diabetics 
including successful renal (and sometimes 
simultaneous pancreas) transplantation.
Predialysis care and problems 
related to renal replacement therapy 
in diabetics
•    Blindness due to retinopathy may preclude 
peritoneal dialysis if a family member is 
not available to help, so regular retinal 
care by an ophthalmologist is essential.
•    Macrovascular disease creates problems 
in making effective fistulae for haemo-
dialysis. The additional burden of 
coronary heart disease and stroke is 
worsened by renal failure that may 
promote atherosclerosis.  Good care 
to modify atherosclerotic risk factors 
should be initiated early in diabetic 
management. Cessation of smoking 
is particulary important because 
smoking is an independent risk factor 
for progression of renal failure, and also 
affects atherosclerosis.
•    Neuropathy, both peripheral and 
autonomic, may be worsened by renal 
failure and can cause problems with 
blood pressure control on dialysis, nausea 
and vomiting due to gastroparesis and 
orthostatic hypotension.
•    Anaemia and bone disease management 
should not be neglected.
Management of diabetic 
renal disease
In our armamentarium we have glucose 
control, antihypertensive treatment, 
particularly targeting the renin-angiotensin 
system and restriction of dietary protein.
All type 1 diabetics over 12 years of 
age should be screened annually for 
microalbuminuria from 5 years after the 
diagnosis of diabetes has been made, 
while type 2 diabetics should start 
immediately with annual screening.
One of the few 
places where small 
blood vessels 
can be observed 
directly is in the 
retina – clinicians 
should therefore 
not lose their 
ability to use an 
ophthalmoscope.
Table II. Indications for renal biopsy or other investigations in diabetic 
renal disease
•    The absence of retinopathy, specifically in type 1 diabetics
•    Rapid onset of severe proteinuria, with a short duration of diabetes (< 5 years) (type 2 
diabetics may have proteinuria soon after the diagnosis is made)
•    With macroscopic haematuria – microscopic haematuria does occur in diabetic  
nephropathy, but macroscopic haematuria may indicate papillary necrosis or a  
glomerulonephritis (IgA)
•    Active urinary sediment, particularly red cell casts
•    Rapid decline in renal function without significant proteinuria, particularly in type 2 
diabetics when atherosclerotic renovascular disease should be considered; usually a 
Doppler investigation of renal arteries, or an MR angiography are done as screening 
tests
•    If serological tests suggest another disease (such as antinuclear factor (ANF), antineu-
trophil cytoplasmic antibody (ANCA), etc.)
August  2007  Vol.25  No.8  CME




Although good glucose control is important 
in all diabetics, we have good evidence 
that, particularly in early disease, it may 
prevent progression. The DCCT trial 
showed that normoalbuminuric patients 
had a smaller chance of developing 
microalbuminuria with tight glucose 
control. When microalbuminuria and later 
overt nephropathy occur, the effect of good 
glucose control, although probably still 
beneficial, is not so clear and the effect of 
hypertension may start to predominate.
Antihypertensive therapy
Hypertension (BP > 140/90 mmHg) usu-
ally starts within a few years of the onset 
of microalbuminuria, and control of 
blood pressure has been shown to have a 
major beneficial effect on proteinuria and 
preservation of renal function. A lower 
threshold for starting antihypertensives 
(130/80 mmHg) and a lower target blood 
pressure4 are advocated by most guidelines 
in use today.  How low to go is not absolutely 
clear at this stage, but the more proteinuria 
is present, the lower a target should probably 
be chosen.  There is some evidence that all 
antihypertensives are not equal and those 
affecting the renin-angiotensin system are of 
particular benefit.
ACE-inhibitors and angiotensin 
receptor blockade (ARB)
Few studies are available in normotensive 
diabetics with normoalbuminuria that 
show benefit in preventing the onset of 
microalbuminuria by early use of ACE-
inhibitors. However, several studies have 
documented their beneficial effect once 
microalbuminuria occurs, even without 
hypertension, and they may delay the 
onset of overt proteinuria. Most studies 
with ACE-inhibitors have been done in 
type 1 diabetics but several studies with 
type 2 diabetics using ARBs are available 
with similar results. The DETAIL5 trial 
compared an ACE-inhibitor with an ARB 
directly in type 2 diabetics and found them 
equally effective. To control proteinuria it 
may be necessary to use a combination of 
an ACE-inhibitor and an ARB. However, 
the development of hyperkalaemia may be 
prohibitive, particularly in those patients 
with hyporeninaemic hypoaldosteronism.
Dietary protein intake
Dietary protein restriction may improve 
uraemic symptoms and in some instances 
retard progression of renal disease, although 
this was not proven in all studies.  The problem 
is that patients who are malnourished (as 
evidenced by hypoalbuminaemia) and who 
are started on dialysis, do worse on renal 
replacement therapy. Most nephrologists 
advocate a protein restriction of 0.8 g/kg/day 
with care not to allow the patient to become 
malnourished. Although it is generally 
suggested that a diabetic with stage 5 renal 
failure should be started earlier on dialysis, 
in South Africa most of these patients in the 
public sector are refused chronic dialysis 
– therefore dietary protein restriction will 
remain part of our management.
Table III summarises the management of 
diabetic nephropathy.
Conclusion
Clinicians have an added responsibility to 
optimise care of diabetic patients in South 
Africa, because renal replacement is not 
an option for a significant group of these 
patients. We should always control glucose 
as well as possible and start an ACE-
inhibitor when microalbuminuria occurs, 
irrespective of the blood pressure. When 
overt nephropathy occurs, meticulous 
blood pressure control (using drugs acting 
against angiotensin, among others), is 
necessary, regularly monitoring both blood 
pressure and proteinuria, with targets of 
blood pressure lower than those of the 
general hypertensive population. Even if 
the blood pressure is controlled medication 
may have to be increased further to reduce 
proteinuria. All possible modifiable risk 
factors for atherosclerosis should be 
identified and controlled. Any unnecessary 
additional insults to the kidneys should be 
avoided when possible, such as contrast-
induced nephrotoxicity, analgesics, NSAIDs 
and aminoglycosides. Timely preparation 
for early renal replacement therapy should 
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Table III. Management of diabetic nephropathy in a nutshell
Stage   Management   Monitor
Early   Optimise glycaemic control  HbA1c < 7% 
microalbuminuria  ACE–inhibitor or ARB                 Urine prot/creat ratio 
   (even with normal BP)     
Proteinuria  Aggressive BP control  BP < 130/80 or less 
Renal failure  0.8 g/kg/day protein restriction Risk factors for  
   Early dialysis   atherosclerosis
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